<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37744367</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>NETosis: an emerging therapeutic target in renal diseases.</ArticleTitle><Pagination><StartPage>1253667</StartPage><MedlinePgn>1253667</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1253667</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1253667</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Neutrophil extracellular traps (NETs) are web-like structures composed of nuclear and granular components. The primary role of NETS is to prevent the dissemination of microbes and facilitate their elimination. However, this process is accompanied by collateral proinflammatory adverse effects when the NET release becomes uncontrollable, or clearance is impaired. Although NET-induced organ damage is conducted primarily and indirectly via immune complexes and the subsequent release of cytokines, their direct effects on cells are also remarkable. NETosis plays a critical pathogenic role in several renal disorders, such as the early phase of acute tubular necrosis, anti-neutrophil cytoplasmic antibody-mediated renal vasculitis, lupus nephritis, thrombotic microangiopathies, anti-glomerular basement membrane disease, and diabetic nephropathy. Their substantial contribution in the course of these disorders makes them a desirable target in the therapeutic armamentarium. This article gives an in-depth review of the heterogeneous pathogenesis and physiological regulations of NETosis and its pivotal role in renal diseases. Based on the pathogenesis, the article also outlines the current therapeutic options and possible molecular targets in the treatment of NET-related renal disorders.</AbstractText><AbstractText Label="METHODS">We carried out thorough literature research published in PubMed and Google Scholar, including a comprehensive review and analysis of the classification, pathomechanisms, and a broad spectrum of NET-related kidney disorders.</AbstractText><AbstractText Label="CONCLUSIONS">NETosis plays a pivotal role in certain renal diseases. It initiates and maintains inflammatory and autoimmune disorders, thus making it a desirable target for improving patient and renal outcomes. Better understanding and clinical translation of the pathogenesis are crucial aspects to treatment, for improving patient, and renal outcomes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Juha, Moln&#xe1;r, Jakus and Led&#xf3;.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Juha</LastName><ForeName>M&#xe1;rk</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moln&#xe1;r</LastName><ForeName>Ad&#xe9;l</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jakus</LastName><ForeName>Zolt&#xe1;n</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Physiology, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Led&#xf3;</LastName><ForeName>N&#xf3;ra</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019268">Antibodies, Antineutrophil Cytoplasmic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003928" MajorTopicYN="Y">Diabetic Nephropathies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019867" MajorTopicYN="Y">Anti-Glomerular Basement Membrane Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019268" MajorTopicYN="N">Antibodies, Antineutrophil Cytoplasmic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ANCA associated vasculitis</Keyword><Keyword MajorTopicYN="N">NETosis</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">neutrophil extracellular traps</Keyword><Keyword MajorTopicYN="N">renal diseases</Keyword></KeywordList><CoiStatement>All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>26</Day><Hour>13</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>25</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37744367</ArticleId><ArticleId IdType="pmc">PMC10514582</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1253667</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Burn GL, Foti A, Marsman G, Patel DF, Zychlinsky A. The neutrophil. Immunity (2021) 54(7):1377&#x2013;91. doi:&#xa0;10.1016/j.immuni.2021.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.06.006</ArticleId><ArticleId IdType="pubmed">34260886</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Kaplan MJ. The role of neutrophils and netosis in autoimmune and renal diseases. Nat Rev Nephrol (2016) 12(7):402&#x2013;13. doi:&#xa0;10.1038/nrneph.2016.71</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2016.71</ArticleId><ArticleId IdType="pmc">PMC5510606</ArticleId><ArticleId IdType="pubmed">27241241</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal AW. How neutrophils kill microbes. Annu Rev Immunol (2005) 23:197&#x2013;223. doi:&#xa0;10.1146/annurev.immunol.23.021704.115653</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.23.021704.115653</ArticleId><ArticleId IdType="pmc">PMC2092448</ArticleId><ArticleId IdType="pubmed">15771570</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. . Neutrophil extracellular traps kill bacteria. Science (2004) 303(5663):1532&#x2013;5. doi:&#xa0;10.1126/science.1092385</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1092385</ArticleId><ArticleId IdType="pubmed">15001782</ArticleId></ArticleIdList></Reference><Reference><Citation>Renehan AG, Booth C, Potten CS. What is apoptosis, and why is it important? BMJ (2001) 322(7301):1536&#x2013;8. doi:&#xa0;10.1136/bmj.322.7301.1536</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.322.7301.1536</ArticleId><ArticleId IdType="pmc">PMC1120576</ArticleId><ArticleId IdType="pubmed">11420279</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei X, Xie F, Zhou X, Wu Y, Yan H, Liu T, et al. . Role of pyroptosis in inflammation and cancer. Cell Mol Immunol (2022) 19(9):971&#x2013;92. doi:&#xa0;10.1038/s41423-022-00905-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-022-00905-x</ArticleId><ArticleId IdType="pmc">PMC9376585</ArticleId><ArticleId IdType="pubmed">35970871</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan FK-M, Nailwal H, Moriwaki K. Targeting necroptosis in antitumor therapy. In: Johnson DE, editor. Targeting Cell Survival Pathways to Enhance Response to Chemotherapy, vol. 3. Cambridge, Massachusetts, United States: Academic Press; (2019). p. 275&#x2013;85.</Citation></Reference><Reference><Citation>Yu Z, Jiang N, Su W, Zhuo Y. Necroptosis: A novel pathway in neuroinflammation. Front Pharmacol (2021) 12:701564. doi:&#xa0;10.3389/fphar.2021.701564</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.701564</ArticleId><ArticleId IdType="pmc">PMC8311004</ArticleId><ArticleId IdType="pubmed">34322024</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei H, Araki A, Watanabe H, Ichinose A, Sendo F. Rapid killing of human neutrophils by the potent activator Phorbol 12-myristate 13-acetate (Pma) accompanied by changes different from typical apoptosis or necrosis. J Leukoc Biol (1996) 59(2):229&#x2013;40. doi:&#xa0;10.1002/jlb.59.2.229</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jlb.59.2.229</ArticleId><ArticleId IdType="pubmed">8603995</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD, Jr., et al. . Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA (2010) 107(36):15880&#x2013;5. doi:&#xa0;10.1073/pnas.1005743107</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1005743107</ArticleId><ArticleId IdType="pmc">PMC2936604</ArticleId><ArticleId IdType="pubmed">20798043</ArticleId></ArticleIdList></Reference><Reference><Citation>Doring Y, Libby P, Soehnlein O. Neutrophil extracellular traps participate in cardiovascular diseases: recent experimental and clinical insights. Circ Res (2020) 126(9):1228&#x2013;41. doi:&#xa0;10.1161/CIRCRESAHA.120.315931</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.315931</ArticleId><ArticleId IdType="pmc">PMC7185047</ArticleId><ArticleId IdType="pubmed">32324499</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedervall J, Hamidi A, Olsson AK. Platelets, nets and cancer. Thromb Res (2018) 164 Suppl 1:S148&#x2013;S52. doi:&#xa0;10.1016/j.thromres.2018.01.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2018.01.049</ArticleId><ArticleId IdType="pubmed">29703474</ArticleId></ArticleIdList></Reference><Reference><Citation>Wigerblad G, Kaplan MJ. Nets spread ever wider in rheumatic diseases. Nat Rev Rheumatol (2020) 16(2):73&#x2013;4. doi:&#xa0;10.1038/s41584-019-0352-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-019-0352-1</ArticleId><ArticleId IdType="pubmed">31853047</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KH, Kronbichler A, Park DD, Park Y, Moon H, Kim H, et al. . Neutrophil extracellular traps (Nets) in autoimmune diseases: A comprehensive review. Autoimmun Rev (2017) 16(11):1160&#x2013;73. doi:&#xa0;10.1016/j.autrev.2017.09.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2017.09.012</ArticleId><ArticleId IdType="pubmed">28899799</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorobjeva NV, Chernyak BV. Netosis: molecular mechanisms, role in physiology and pathology. Biochem (Mosc) (2020) 85(10):1178&#x2013;90. doi:&#xa0;10.1134/S0006297920100065</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/S0006297920100065</ArticleId><ArticleId IdType="pmc">PMC7590568</ArticleId><ArticleId IdType="pubmed">33202203</ArticleId></ArticleIdList></Reference><Reference><Citation>Petretto A, Bruschi M, Pratesi F, Croia C, Candiano G, Ghiggeri G, et al. . Neutrophil extracellular traps (Net) induced by different stimuli: A comparative proteomic analysis. PloS One (2019) 14(7):e0218946. doi:&#xa0;10.1371/journal.pone.0218946</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0218946</ArticleId><ArticleId IdType="pmc">PMC6613696</ArticleId><ArticleId IdType="pubmed">31283757</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bont CM, Boelens WC, Pruijn GJM. Netosis, complement, and coagulation: A triangular relationship. Cell Mol Immunol (2019) 16(1):19&#x2013;27. doi:&#xa0;10.1038/s41423-018-0024-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-018-0024-0</ArticleId><ArticleId IdType="pmc">PMC6318284</ArticleId><ArticleId IdType="pubmed">29572545</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan MJ, Radic M. Neutrophil extracellular traps: double-edged swords of innate immunity. J Immunol (2012) 189(6):2689&#x2013;95. doi:&#xa0;10.4049/jimmunol.1201719</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1201719</ArticleId><ArticleId IdType="pmc">PMC3439169</ArticleId><ArticleId IdType="pubmed">22956760</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Biermann MH, Brauner JM, Liu Y, Zhao Y, Herrmann M. New insights into neutrophil extracellular traps: mechanisms of formation and role in inflammation. Front Immunol (2016) 7:302. doi:&#xa0;10.3389/fimmu.2016.00302</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00302</ArticleId><ArticleId IdType="pmc">PMC4981595</ArticleId><ArticleId IdType="pubmed">27570525</ArticleId></ArticleIdList></Reference><Reference><Citation>Speziale P, Pietrocola G. Staphylococcus aureus induces neutrophil extracellular traps (Nets) and neutralizes their bactericidal potential. Comput Struct Biotechnol J (2021) 19:3451&#x2013;7. doi:&#xa0;10.1016/j.csbj.2021.06.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2021.06.012</ArticleId><ArticleId IdType="pmc">PMC8220102</ArticleId><ArticleId IdType="pubmed">34194670</ArticleId></ArticleIdList></Reference><Reference><Citation>Metzler Kathleen D, Goosmann C, Lubojemska A, Zychlinsky A, Papayannopoulos V. A myeloperoxidase-containing complex regulates neutrophil elastase release and actin dynamics during netosis. Cell Rep (2014) 8(3):883&#x2013;96. doi:&#xa0;10.1016/j.celrep.2014.06.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.06.044</ArticleId><ArticleId IdType="pmc">PMC4471680</ArticleId><ArticleId IdType="pubmed">25066128</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosswein S, Lindemann A, Mahajan A, Maueroder C, Martini E, Patankar J, et al. . Citrullination licenses calpain to decondense nuclei in neutrophil extracellular trap formation. Front Immunol (2019) 10:2481. doi:&#xa0;10.3389/fimmu.2019.02481</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02481</ArticleId><ArticleId IdType="pmc">PMC6817590</ArticleId><ArticleId IdType="pubmed">31695698</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiam HR, Wong SL, Wagner DD, Waterman CM. Cellular mechanisms of netosis. Annu Rev Cell Dev Biol (2020) 36:191&#x2013;218. doi:&#xa0;10.1146/annurev-cellbio-020520-111016</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-cellbio-020520-111016</ArticleId><ArticleId IdType="pmc">PMC8499668</ArticleId><ArticleId IdType="pubmed">32663035</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagiwara T, Hidaka Y, Yamada M. Deimination of histone H2a and H4 at arginine 3 in Hl-60 granulocytes. Biochemistry (2005) 44(15):5827&#x2013;34. doi:&#xa0;10.1021/bi047505c</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi047505c</ArticleId><ArticleId IdType="pubmed">15823041</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilley DO, Abuabed U, Zimny Arndt U, Schmid M, Florian S, Jungblut PR, et al. . Histone H3 clipping is a novel signature of human neutrophil extracellular traps. Elife (2022) 11:e68283. doi:&#xa0;10.7554/eLife.68283</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.68283</ArticleId><ArticleId IdType="pmc">PMC9665850</ArticleId><ArticleId IdType="pubmed">36282064</ArticleId></ArticleIdList></Reference><Reference><Citation>Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol (2010) 191(3):677&#x2013;91. doi:&#xa0;10.1083/jcb.201006052</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201006052</ArticleId><ArticleId IdType="pmc">PMC3003309</ArticleId><ArticleId IdType="pubmed">20974816</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanheira FVS, Kubes P. Neutrophils and nets in modulating acute and chronic inflammation. Blood (2019) 133(20):2178&#x2013;85. doi:&#xa0;10.1182/blood-2018-11-844530</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-11-844530</ArticleId><ArticleId IdType="pubmed">30898862</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Li M, Lindberg MR, Kennett MJ, Xiong N, Wang Y. Pad4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J Exp Med (2010) 207(9):1853&#x2013;62. doi:&#xa0;10.1084/jem.20100239</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20100239</ArticleId><ArticleId IdType="pmc">PMC2931169</ArticleId><ArticleId IdType="pubmed">20733033</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiam HR, Wong SL, Qiu R, Kittisopikul M, Vahabikashi A, Goldman AE, et al. . Netosis proceeds by cytoskeleton and endomembrane disassembly and pad4-mediated chromatin decondensation and nuclear envelope rupture. Proc Natl Acad Sci (2020) 117(13):7326&#x2013;37. doi:&#xa0;10.1073/pnas.1909546117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1909546117</ArticleId><ArticleId IdType="pmc">PMC7132277</ArticleId><ArticleId IdType="pubmed">32170015</ArticleId></ArticleIdList></Reference><Reference><Citation>Hidalgo A, Libby P, Soehnlein O, Aramburu IV, Papayannopoulos V, Silvestre-Roig C. Neutrophil extracellular traps: from physiology to pathology. Cardiovasc Res (2022) 118(13):2737&#x2013;53. doi:&#xa0;10.1093/cvr/cvab329</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvab329</ArticleId><ArticleId IdType="pmc">PMC9586562</ArticleId><ArticleId IdType="pubmed">34648022</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen KW, Monteleone M, Boucher D, Sollberger G, Ramnath D, Condon ND, et al. . Noncanonical inflammasome signaling elicits gasdermin D-dependent neutrophil extracellular traps. Sci Immunol (2018) 3(26):eaar6676. doi:&#xa0;10.1126/sciimmunol.aar6676</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.aar6676</ArticleId><ArticleId IdType="pubmed">30143554</ArticleId></ArticleIdList></Reference><Reference><Citation>Douda DN, Khan MA, Grasemann H, Palaniyar N. Sk3 channel and mitochondrial ros mediate nadph oxidase-independent netosis induced by calcium influx. Proc Natl Acad Sci (2015) 112(9):2817&#x2013;22. doi:&#xa0;10.1073/pnas.1414055112</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1414055112</ArticleId><ArticleId IdType="pmc">PMC4352781</ArticleId><ArticleId IdType="pubmed">25730848</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousefi S, Mihalache C, Kozlowski E, Schmid I, Simon HU. Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps. Cell Death Differ (2009) 16(11):1438&#x2013;44. doi:&#xa0;10.1038/cdd.2009.96</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2009.96</ArticleId><ArticleId IdType="pubmed">19609275</ArticleId></ArticleIdList></Reference><Reference><Citation>Lood C, Blanco LP, Purmalek MM, Carmona-Rivera C, De Ravin SS, Smith CK, et al. . Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat Med (2016) 22(2):146&#x2013;53. doi:&#xa0;10.1038/nm.4027</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4027</ArticleId><ArticleId IdType="pmc">PMC4742415</ArticleId><ArticleId IdType="pubmed">26779811</ArticleId></ArticleIdList></Reference><Reference><Citation>Singhal A, Kumar S. Neutrophil and remnant clearance in immunity and inflammation. Immunology (2022) 165(1):22&#x2013;43. doi:&#xa0;10.1111/imm.13423</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13423</ArticleId><ArticleId IdType="pubmed">34704249</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakazawa D, Shida H, Kusunoki Y, Miyoshi A, Nishio S, Tomaru U, et al. . The responses of macrophages in interaction with neutrophils that undergo netosis. J Autoimmun (2016) 67:19&#x2013;28. doi:&#xa0;10.1016/j.jaut.2015.08.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2015.08.018</ArticleId><ArticleId IdType="pubmed">26347075</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundert F, Platen L, Iwakura T, Zhao Z, Marschner JA, Anders H-J. Immune mechanisms in the different phases of acute tubular necrosis. Kidney Res Clin Pract (2018) 37(3):185&#x2013;96. doi:&#xa0;10.23876/j.krcp.2018.37.3.185</Citation><ArticleIdList><ArticleId IdType="doi">10.23876/j.krcp.2018.37.3.185</ArticleId><ArticleId IdType="pmc">PMC6147180</ArticleId><ArticleId IdType="pubmed">30254843</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrera C, Fadeel B. Macrophage clearance of neutrophil extracellular traps is a silent process. J Immunol (2013) 191(5):2647&#x2013;56. doi:&#xa0;10.4049/jimmunol.1300436</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1300436</ArticleId><ArticleId IdType="pubmed">23904163</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazzaretto B, Fadeel B. Intra- and extracellular degradation of neutrophil extracellular traps by macrophages and dendritic cells. J Immunol (2019) 203(8):2276&#x2013;90. doi:&#xa0;10.4049/jimmunol.1800159</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1800159</ArticleId><ArticleId IdType="pmc">PMC6778307</ArticleId><ArticleId IdType="pubmed">31519860</ArticleId></ArticleIdList></Reference><Reference><Citation>Roszer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm (2015) 2015:816460. doi:&#xa0;10.1155/2015/816460</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/816460</ArticleId><ArticleId IdType="pmc">PMC4452191</ArticleId><ArticleId IdType="pubmed">26089604</ArticleId></ArticleIdList></Reference><Reference><Citation>Angeletti A, Volpi S, Bruschi M, Lugani F, Vaglio A, Prunotto M, et al. . Neutrophil extracellular traps-Dnase balance and autoimmunity. Cells (2021) 10(10):2667. doi:&#xa0;10.3390/cells10102667</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10102667</ArticleId><ArticleId IdType="pmc">PMC8534732</ArticleId><ArticleId IdType="pubmed">34685647</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisirak V, Sally B, D&#x2019;Agati V, Martinez-Ortiz W, &#xd6;z&#xe7;akar ZB, David J, et al. . Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity. Cell (2016) 166(1):88&#x2013;101. doi:&#xa0;10.1016/j.cell.2016.05.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.05.034</ArticleId><ArticleId IdType="pmc">PMC5030815</ArticleId><ArticleId IdType="pubmed">27293190</ArticleId></ArticleIdList></Reference><Reference><Citation>Napirei M, Wulf S, Mannherz HG. Chromatin breakdown during necrosis by serum Dnase1 and the plasminogen system. Arthritis Rheum (2004) 50(6):1873&#x2013;83. doi:&#xa0;10.1002/art.20267</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20267</ArticleId><ArticleId IdType="pubmed">15188364</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman AL, Mocatta TJ, Shiva S, Seidel A, Chen B, Khalilova I, et al. . Ceruloplasmin is an endogenous inhibitor of Myeloperoxidase. J Biol Chem (2013) 288(9):6465&#x2013;77. doi:&#xa0;10.1074/jbc.M112.418970</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.418970</ArticleId><ArticleId IdType="pmc">PMC3585080</ArticleId><ArticleId IdType="pubmed">23306200</ArticleId></ArticleIdList></Reference><Reference><Citation>Duranton J, Bieth JG. Inhibition of proteinase 3 by [Alpha]1-Antitrypsin in vitro predicts very fast inhibition in vivo. Am J Respir Cell Mol Biol (2003) 29(1):57&#x2013;61. doi:&#xa0;10.1165/rcmb.2002-0258OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2002-0258OC</ArticleId><ArticleId IdType="pubmed">12600819</ArticleId></ArticleIdList></Reference><Reference><Citation>Jariwala MP, Laxer RM. Netosis in rheumatic diseases. Curr Rheumatol Rep (2021) 23(2):9. doi:&#xa0;10.1007/s11926-020-00977-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-020-00977-6</ArticleId><ArticleId IdType="pubmed">33511473</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Xiao Y, Zhong L, Ye D, Zhang J, Tu Y, et al. . Increased neutrophil elastase and proteinase 3 and augmented netosis are closely associated with &#x3b2;-cell autoimmunity in patients with type 1 diabetes. Diabetes (2014) 63(12):4239&#x2013;48. doi:&#xa0;10.2337/db14-0480</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db14-0480</ArticleId><ArticleId IdType="pubmed">25092677</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennike TB, Carlsen TG, Ellingsen T, Bonderup OK, Glerup H, Bogsted M, et al. . Neutrophil extracellular traps in ulcerative colitis: A proteome analysis of intestinal biopsies. Inflamm Bowel Dis (2015) 21(9):2052&#x2013;67. doi:&#xa0;10.1097/MIB.0000000000000460</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MIB.0000000000000460</ArticleId><ArticleId IdType="pmc">PMC4603666</ArticleId><ArticleId IdType="pubmed">25993694</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Wang C, Liu Y, Li B, Zhang W, Wang L, et al. . Neutrophil extracellular traps induce intestinal damage and thrombotic tendency in inflammatory bowel disease. J Crohns Colitis (2020) 14(2):240&#x2013;53. doi:&#xa0;10.1093/ecco-jcc/jjz132</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjz132</ArticleId><ArticleId IdType="pubmed">31325355</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitroulis I, Kambas K, Chrysanthopoulou A, Skendros P, Apostolidou E, Kourtzelis I, et al. . Neutrophil extracellular trap formation is associated with Il-1&#x3b2; and autophagy-related signaling in gout. PloS One (2011) 6(12):e29318. doi:&#xa0;10.1371/journal.pone.0029318</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0029318</ArticleId><ArticleId IdType="pmc">PMC3241704</ArticleId><ArticleId IdType="pubmed">22195044</ArticleId></ArticleIdList></Reference><Reference><Citation>Gestermann N, Di Domizio J, Lande R, Demaria O, Frasca L, Feldmeyer L, et al. . Netting neutrophils activate autoreactive B cells in lupus. J Immunol (2018) 200(10):3364&#x2013;71. doi:&#xa0;10.4049/jimmunol.1700778</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1700778</ArticleId><ArticleId IdType="pubmed">29632142</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanujam M, Davidson A. The current status of targeting Baff/Blys for autoimmune diseases. Arthritis Res Ther (2004) 6(5):197. doi:&#xa0;10.1186/ar1222</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar1222</ArticleId><ArticleId IdType="pmc">PMC546289</ArticleId><ArticleId IdType="pubmed">15380033</ArticleId></ArticleIdList></Reference><Reference><Citation>Granger V, Peyneau M, Chollet-Martin S, de Chaisemartin L. Neutrophil extracellular traps in autoimmunity and allergy: immune complexes at work. Front Immunol (2019) 10:2824. doi:&#xa0;10.3389/fimmu.2019.02824</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02824</ArticleId><ArticleId IdType="pmc">PMC6901596</ArticleId><ArticleId IdType="pubmed">31849989</ArticleId></ArticleIdList></Reference><Reference><Citation>Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, et al. . Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic Lupus Erythematosus. Sci Transl Med (2011) 3(73):73ra19. doi:&#xa0;10.1126/scitranslmed.3001180</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3001180</ArticleId><ArticleId IdType="pmc">PMC3399524</ArticleId><ArticleId IdType="pubmed">21389263</ArticleId></ArticleIdList></Reference><Reference><Citation>Fousert E, Toes R, Desai J. Neutrophil extracellular traps (Nets) take the central stage in driving autoimmune responses. Cells (2020) 9(4):915. doi:&#xa0;10.3390/cells9040915</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9040915</ArticleId><ArticleId IdType="pmc">PMC7226846</ArticleId><ArticleId IdType="pubmed">32276504</ArticleId></ArticleIdList></Reference><Reference><Citation>Kienh&#xf6;fer D, Hahn J, Stoof J, Csepregi JZ, Reinwald C, Urbonaviciute V, et al. . Experimental lupus is aggravated in mouse strains with impaired induction of neutrophil extracellular traps. JCI Insight (2017) 2(10):e92920. doi:&#xa0;10.1172/jci.insight.92920</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.92920</ArticleId><ArticleId IdType="pmc">PMC5436535</ArticleId><ArticleId IdType="pubmed">28515366</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q, Choksi S, Qu J, Jang J, Choe M, Banfi B, et al. . Nadph oxidases are essential for macrophage differentiation. J Biol Chem (2016) 291(38):20030&#x2013;41. doi:&#xa0;10.1074/jbc.M116.731216</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.731216</ArticleId><ArticleId IdType="pmc">PMC5025689</ArticleId><ArticleId IdType="pubmed">27489105</ArticleId></ArticleIdList></Reference><Reference><Citation>McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PloS Med (2006) 3(8):e297. doi:&#xa0;10.1371/journal.pmed.0030297</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0030297</ArticleId><ArticleId IdType="pmc">PMC1564298</ArticleId><ArticleId IdType="pubmed">16942393</ArticleId></ArticleIdList></Reference><Reference><Citation>Szekanecz Z, McInnes IB, Schett G, Szamosi S, Benk&#x151; S, Sz&#x171;cs G. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat Rev Rheumatol (2021) 17(10):585&#x2013;95. doi:&#xa0;10.1038/s41584-021-00652-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-021-00652-9</ArticleId><ArticleId IdType="pubmed">34341562</ArticleId></ArticleIdList></Reference><Reference><Citation>Szekanecz Z, Szamosi S, Kov&#xe1;cs GE, Kocsis E, Benk&#x151; S. The Nlrp3 inflammasome - interleukin 1 pathway as a therapeutic target in gout. Arch Biochem Biophysics (2019) 670:82&#x2013;93. doi:&#xa0;10.1016/j.abb.2019.01.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abb.2019.01.031</ArticleId><ArticleId IdType="pubmed">30710503</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinon F, Aksentijevich I. New players driving inflammation in monogenic autoinflammatory diseases. Nat Rev Rheumatol (2015) 11(1):11&#x2013;20. doi:&#xa0;10.1038/nrrheum.2014.158</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2014.158</ArticleId><ArticleId IdType="pubmed">25247411</ArticleId></ArticleIdList></Reference><Reference><Citation>Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 12:991&#x2013;1045. doi:&#xa0;10.1146/annurev.iy.12.040194.005015</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.iy.12.040194.005015</ArticleId><ArticleId IdType="pubmed">8011301</ArticleId></ArticleIdList></Reference><Reference><Citation>Grayson PC, Kaplan MJ. At the bench: neutrophil extracellular traps (Nets) highlight novel aspects of innate immune system involvement in autoimmune diseases. J Leukoc Biol (2016) 99(2):253&#x2013;64. doi:&#xa0;10.1189/jlb.5BT0615-247R</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.5BT0615-247R</ArticleId><ArticleId IdType="pmc">PMC4718195</ArticleId><ArticleId IdType="pubmed">26432901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahlenberg JM, Carmona-Rivera C, Smith CK, Kaplan MJ. Neutrophil extracellular trap-associated protein activation of the Nlrp3 inflammasome is enhanced in lupus macrophages. J Immunol (2013) 190(3):1217&#x2013;26. doi:&#xa0;10.4049/jimmunol.1202388</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1202388</ArticleId><ArticleId IdType="pmc">PMC3552129</ArticleId><ArticleId IdType="pubmed">23267025</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmona-Rivera C, Zhao W, Yalavarthi S, Kaplan MJ. Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2. Ann Rheum Dis (2015) 74(7):1417&#x2013;24. doi:&#xa0;10.1136/annrheumdis-2013-204837</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-204837</ArticleId><ArticleId IdType="pmc">PMC4143484</ArticleId><ArticleId IdType="pubmed">24570026</ArticleId></ArticleIdList></Reference><Reference><Citation>Ter Haar NM, Jansen MHA, Frenkel JF, Vastert SJ. How autoinflammation may turn into autoimmune inflammation: insights from monogenetic and complex Il-1 mediated auto-inflammatory diseases. Clin Immunol (2020) 219:108538. doi:&#xa0;10.1016/j.clim.2020.108538</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108538</ArticleId><ArticleId IdType="pubmed">32681980</ArticleId></ArticleIdList></Reference><Reference><Citation>Mozzini C, Garbin U, Fratta Pasini AM, Cominacini L. An exploratory look at netosis in atherosclerosis. Internal Emergency Med (2017) 12(1):13&#x2013;22. doi:&#xa0;10.1007/s11739-016-1543-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-016-1543-2</ArticleId><ArticleId IdType="pubmed">27655025</ArticleId></ArticleIdList></Reference><Reference><Citation>Stakos DA, Kambas K, Konstantinidis T, Mitroulis I, Apostolidou E, Arelaki S, et al. . Expression of functional tissue factor by neutrophil extracellular traps in culprit artery of acute myocardial infarction. Eur Heart J (2015) 36(22):1405&#x2013;14. doi:&#xa0;10.1093/eurheartj/ehv007</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehv007</ArticleId><ArticleId IdType="pmc">PMC4458286</ArticleId><ArticleId IdType="pubmed">25660055</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Ishikawa T, Lai Y, Nallapothula D, Singh RR. Diverse roles of netosis in the pathogenesis of lupus. Front Immunol (2022) 13:895216. doi:&#xa0;10.3389/fimmu.2022.895216</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.895216</ArticleId><ArticleId IdType="pmc">PMC9170953</ArticleId><ArticleId IdType="pubmed">35686129</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny MF, Yalavarthi S, Zhao W, Thacker SG, Anderson M, Sandy AR, et al. . A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I Ifns. J Immunol (2010) 184(6):3284&#x2013;97. doi:&#xa0;10.4049/jimmunol.0902199</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0902199</ArticleId><ArticleId IdType="pmc">PMC2929645</ArticleId><ArticleId IdType="pubmed">20164424</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CK, Vivekanandan-Giri A, Tang C, Knight JS, Mathew A, Padilla RL, et al. . Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus. Arthritis Rheumatol (2014) 66(9):2532&#x2013;44. doi:&#xa0;10.1002/art.38703</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38703</ArticleId><ArticleId IdType="pmc">PMC4146708</ArticleId><ArticleId IdType="pubmed">24838349</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaul ME, Fridlender ZG. Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol (2019) 16(10):601&#x2013;20. doi:&#xa0;10.1038/s41571-019-0222-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-019-0222-4</ArticleId><ArticleId IdType="pubmed">31160735</ArticleId></ArticleIdList></Reference><Reference><Citation>Homa-Mlak I, Majdan A, Mlak R, Malecka-Massalska T. Metastatic potential of net in neoplastic disease. Postepy Hig Med Dosw (2016) 70(0):887&#x2013;95. doi:&#xa0;10.5604/17322693.1216275</Citation><ArticleIdList><ArticleId IdType="doi">10.5604/17322693.1216275</ArticleId><ArticleId IdType="pubmed">27594564</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar SV, Kulkarni OP, Mulay SR, Darisipudi MN, Romoli S, Thomasova D, et al. . Neutrophil extracellular trap-related extracellular histones cause vascular necrosis in severe Gn. J Am Soc Nephrol (2015) 26(10):2399&#x2013;413. doi:&#xa0;10.1681/ASN.2014070673</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2014070673</ArticleId><ArticleId IdType="pmc">PMC4587690</ArticleId><ArticleId IdType="pubmed">25644111</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltran-Garcia J, Osca-Verdegal R, Perez-Cremades D, Novella S, Hermenegildo C, Pallardo FV, et al. . Extracellular histones activate endothelial Nlrp3 inflammasome and are associated with a severe sepsis phenotype. J Inflamm Res (2022) 15:4217&#x2013;38. doi:&#xa0;10.2147/JIR.S363693</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S363693</ArticleId><ArticleId IdType="pmc">PMC9338392</ArticleId><ArticleId IdType="pubmed">35915852</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong S, Yang S, Li T, Gao R, Hu J, Luo T, et al. . Role of neutrophil extracellular traps in chronic kidney injury induced by Bisphenol-A. J Endocrinol (2019) 241(2):125&#x2013;34. doi:&#xa0;10.1530/JOE-18-0608</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/JOE-18-0608</ArticleId><ArticleId IdType="pubmed">30798321</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakazawa D, Kumar SV, Marschner J, Desai J, Holderied A, Rath L, et al. . Histones and neutrophil extracellular traps enhance tubular necrosis and remote organ injury in ischemic Aki. J Am Soc Nephrol (2017) 28(6):1753&#x2013;68. doi: 10.1681/ASN.2016080925</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2016080925</ArticleId><ArticleId IdType="pmc">PMC5461800</ArticleId><ArticleId IdType="pubmed">28073931</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmona-Rivera C, Kaplan MJ. Low-density granulocytes: A distinct class of neutrophils in systemic autoimmunity. Semin Immunopathol (2013) 35(4):455&#x2013;63. doi:&#xa0;10.1007/s00281-013-0375-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-013-0375-7</ArticleId><ArticleId IdType="pmc">PMC4007274</ArticleId><ArticleId IdType="pubmed">23553215</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, et al. . Netting neutrophils are major inducers of type I Ifn production in pediatric systemic lupus erythematosus. Sci Transl Med (2011) 3(73):73ra20. doi:&#xa0;10.1126/scitranslmed.3001201</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3001201</ArticleId><ArticleId IdType="pmc">PMC3143837</ArticleId><ArticleId IdType="pubmed">21389264</ArticleId></ArticleIdList></Reference><Reference><Citation>Caielli S, Athale S, Domic B, Murat E, Chandra M, Banchereau R, et al. . Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus. J Exp Med (2016) 213(5):697&#x2013;713. doi:&#xa0;10.1084/jem.20151876</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20151876</ArticleId><ArticleId IdType="pmc">PMC4854735</ArticleId><ArticleId IdType="pubmed">27091841</ArticleId></ArticleIdList></Reference><Reference><Citation>Neubert E, Bach KM, Busse J, Bogeski I, Schon MP, Kruss S, et al. . Blue and long-wave ultraviolet light induce in vitro neutrophil extracellular trap (Net) formation. Front Immunol (2019) 10:2428. doi:&#xa0;10.3389/fimmu.2019.02428</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02428</ArticleId><ArticleId IdType="pmc">PMC6823194</ArticleId><ArticleId IdType="pubmed">31708915</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzouz D, Khan MA, Sweezey N, Palaniyar N. Two-in-one: Uv radiation simultaneously induces apoptosis and netosis. Cell Death Discov (2018) 4(1):51. doi:&#xa0;10.1038/s41420-018-0048-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-018-0048-3</ArticleId><ArticleId IdType="pmc">PMC5919968</ArticleId><ArticleId IdType="pubmed">29736268</ArticleId></ArticleIdList></Reference><Reference><Citation>Pazmandi K, Agod Z, Kumar BV, Szabo A, Fekete T, Sogor V, et al. . Oxidative modification enhances the immunostimulatory effects of extracellular mitochondrial DNA on plasmacytoid dendritic cells. Free Radical Biol Med (2014) 77:281&#x2013;90. doi:&#xa0;10.1016/j.freeradbiomed.2014.09.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2014.09.028</ArticleId><ArticleId IdType="pubmed">25301097</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronnblom L, Leonard D. Interferon pathway in Sle: one key to unlocking the mystery of the disease. Lupus Sci Med (2019) 6(1):e000270. doi:&#xa0;10.1136/lupus-2018-000270</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000270</ArticleId><ArticleId IdType="pmc">PMC6703304</ArticleId><ArticleId IdType="pubmed">31497305</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dam LS, Rabelink TJ, van Kooten C, Teng YKO. Clinical implications of excessive neutrophil extracellular trap formation in renal autoimmune diseases. Kidney Int Rep (2019) 4(2):196&#x2013;211. doi:&#xa0;10.1016/j.ekir.2018.11.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2018.11.005</ArticleId><ArticleId IdType="pmc">PMC6365354</ArticleId><ArticleId IdType="pubmed">30775617</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodano A, Gonzalez A, Ferreiros-Vidal I, Balada E, Ordi J, Carreira P, et al. . Association of a non-synonymous single-nucleotide polymorphism of Dnasei with Sle susceptibility. Rheumatol (Oxf) (2006) 45(7):819&#x2013;23. doi:&#xa0;10.1093/rheumatology/kel019</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kel019</ArticleId><ArticleId IdType="pubmed">16449364</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin HD, Park BL, Kim LH, Lee HS, Kim TY, Bae SC. Common Dnase I polymorphism associated with autoantibody production among systemic lupus erythematosus patients. Hum Mol Genet (2004) 13(20):2343&#x2013;50. doi:&#xa0;10.1093/hmg/ddh275</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddh275</ArticleId><ArticleId IdType="pubmed">15333586</ArticleId></ArticleIdList></Reference><Reference><Citation>Trofimenko AS, Gontar IP, Zborovsky AB, Paramonova OV. Anti-Dnase I antibodies in systemic lupus erythematosus: diagnostic value and share in the enzyme inhibition. Rheumatol Int (2016) 36(4):521&#x2013;9. doi:&#xa0;10.1007/s00296-016-3437-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-016-3437-z</ArticleId><ArticleId IdType="pubmed">26879320</ArticleId></ArticleIdList></Reference><Reference><Citation>Emlen W, Ansari R, Burdick G. DNA-anti-DNA immune complexes. Antibody protection of a discrete DNA fragment from Dnase digestion in vitro. J Clin Invest (1984) 74(1):185&#x2013;90. doi:&#xa0;10.1172/JCI111400</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI111400</ArticleId><ArticleId IdType="pmc">PMC425199</ArticleId><ArticleId IdType="pubmed">6234327</ArticleId></ArticleIdList></Reference><Reference><Citation>Leffler J, Martin M, Gullstrand B, Tyden H, Lood C, Truedsson L, et al. . Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol (2012) 188(7):3522&#x2013;31. doi:&#xa0;10.4049/jimmunol.1102404</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1102404</ArticleId><ArticleId IdType="pubmed">22345666</ArticleId></ArticleIdList></Reference><Reference><Citation>Gehrke N, Mertens C, Zillinger T, Wenzel J, Bald T, Zahn S, et al. . Oxidative damage of DNA confers resistance to cytosolic nuclease Trex1 degradation and potentiates sting-dependent immune sensing. Immunity (2013) 39(3):482&#x2013;95. doi:&#xa0;10.1016/j.immuni.2013.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2013.08.004</ArticleId><ArticleId IdType="pubmed">23993650</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen HL, Horvei KD, Thiyagarajan D, Norby GE, Seredkina N, Moroni G, et al. . Lupus nephritis: low urinary dnase I levels reflect loss of renal Dnase I and may be utilized as a biomarker of disease progression. J Pathol Clin Res (2018) 4(3):193&#x2013;203. doi:&#xa0;10.1002/cjp2.99</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cjp2.99</ArticleId><ArticleId IdType="pmc">PMC6065113</ArticleId><ArticleId IdType="pubmed">29624903</ArticleId></ArticleIdList></Reference><Reference><Citation>Molnar A, Studinger P, Ledo N. Diagnostic and therapeutic approach in anca-associated glomerulonephritis: A review on management strategies. Front Med (Lausanne) (2022) 9:884188. doi:&#xa0;10.3389/fmed.2022.884188</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.884188</ArticleId><ArticleId IdType="pmc">PMC9205443</ArticleId><ArticleId IdType="pubmed">35721093</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Sullivan KM, Holdsworth SR. Neutrophil extracellular traps: A potential therapeutic target in Mpo-Anca associated vasculitis? Front Immunol (2021) 12:635188. doi:&#xa0;10.3389/fimmu.2021.635188</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.635188</ArticleId><ArticleId IdType="pmc">PMC8005609</ArticleId><ArticleId IdType="pubmed">33790907</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, Werb Z, et al. . Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med (2009) 15(6):623&#x2013;5. doi:&#xa0;10.1038/nm.1959</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1959</ArticleId><ArticleId IdType="pmc">PMC2760083</ArticleId><ArticleId IdType="pubmed">19448636</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraaij T, Kamerling SWA, van Dam LS, Bakker JA, Bajema IM, Page T, et al. . Excessive neutrophil extracellular trap formation in Anca-associated vasculitis is independent of Anca. Kidney Int (2018) 94(1):139&#x2013;49. doi:&#xa0;10.1016/j.kint.2018.01.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2018.01.013</ArticleId><ArticleId IdType="pubmed">29606398</ArticleId></ArticleIdList></Reference><Reference><Citation>Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 diabetes and its impact on the immune system. Curr Diabetes Rev (2020) 16(5):442&#x2013;9. doi:&#xa0;10.2174/1573399815666191024085838</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573399815666191024085838</ArticleId><ArticleId IdType="pmc">PMC7475801</ArticleId><ArticleId IdType="pubmed">31657690</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Dong Z. Neutrophil extracellular traps in ischemic Aki: new way to kill. Kidney Int (2018) 93(2):303&#x2013;5. doi:&#xa0;10.1016/j.kint.2017.09.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.09.031</ArticleId><ArticleId IdType="pubmed">29389395</ArticleId></ArticleIdList></Reference><Reference><Citation>Darisipudi MN, Thomasova D, Mulay SR, Brech D, Noessner E, Liapis H, et al. . Uromodulin triggers Il-1&#x3b2;&#x2013;dependent innate immunity via the Nlrp3 inflammasome. J Am Soc Nephrol (2012) 23(11):1783&#x2013;9. doi: 10.1681/ASN.2012040338</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2012040338</ArticleId><ArticleId IdType="pmc">PMC3482735</ArticleId><ArticleId IdType="pubmed">22997256</ArticleId></ArticleIdList></Reference><Reference><Citation>Moln&#xe1;r A, Tisl&#xe9;r A, Dobi D, Peth&#x151; &#xc1;. A unique case of anti-Gbm disease with concomitant Anti-Pla2r positivity. BMC Nephrol (2022) 23(1):337. doi:&#xa0;10.1186/s12882-022-02941-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-022-02941-1</ArticleId><ArticleId IdType="pmc">PMC9587597</ArticleId><ArticleId IdType="pubmed">36271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishi H, Furuhashi K, Cullere X, Saggu G, Miller MJ, Chen Y, et al. . Neutrophil Fc&#x3b3;riia promotes Igg-mediated glomerular neutrophil capture via Abl/Src kinases. J Clin Invest (2017) 127(10):3810&#x2013;26. doi:&#xa0;10.1172/JCI94039</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI94039</ArticleId><ArticleId IdType="pmc">PMC5617671</ArticleId><ArticleId IdType="pubmed">28891817</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K, Nishi H, Travers R, Tsuboi N, Martinod K, Wagner DD, et al. . Endocytosis of soluble immune complexes leads to their clearance by Fcgammariiib but induces neutrophil extracellular traps via Fcgammariia in vivo. Blood (2012) 120(22):4421&#x2013;31. doi:&#xa0;10.1182/blood-2011-12-401133</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-12-401133</ArticleId><ArticleId IdType="pmc">PMC3507149</ArticleId><ArticleId IdType="pubmed">22955924</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinon F, P&#xe9;trilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the Nalp3 inflammasome. Nature (2006) 440(7081):237&#x2013;41. doi:&#xa0;10.1038/nature04516</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04516</ArticleId><ArticleId IdType="pubmed">16407889</ArticleId></ArticleIdList></Reference><Reference><Citation>Wigerblad G, Kaplan MJ. Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Nat Rev Immunol (2023) 23(5):274&#x2013;88. doi:&#xa0;10.1038/s41577-022-00787-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00787-0</ArticleId><ArticleId IdType="pmc">PMC9579530</ArticleId><ArticleId IdType="pubmed">36257987</ArticleId></ArticleIdList></Reference><Reference><Citation>Schauer C, Janko C, Munoz LE, Zhao Y, Kienhofer D, Frey B, et al. . Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat Med (2014) 20(5):511&#x2013;7. doi:&#xa0;10.1038/nm.3547</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3547</ArticleId><ArticleId IdType="pubmed">24784231</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn J, Schauer C, Czegley C, Kling L, Petru L, Schmid B, et al. . Aggregated neutrophil extracellular traps resolve inflammation by proteolysis of cytokines and chemokines and protection from antiproteases. FASEB J (2019) 33(1):1401&#x2013;14. doi:&#xa0;10.1096/fj.201800752R</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201800752R</ArticleId><ArticleId IdType="pmc">PMC6355082</ArticleId><ArticleId IdType="pubmed">30130433</ArticleId></ArticleIdList></Reference><Reference><Citation>Skendros P, Papagoras C, Mitroulis I, Ritis K. Autoinflammation: lessons from the study of familial mediterranean fever. J Autoimmun (2019) 104:102305. doi:&#xa0;10.1016/j.jaut.2019.102305</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2019.102305</ArticleId><ArticleId IdType="pubmed">31337526</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolidou E, Skendros P, Kambas K, Mitroulis I, Konstantinidis T, Chrysanthopoulou A, et al. . Neutrophil extracellular traps regulate Il-1beta-mediated inflammation in familial mediterranean fever. Ann Rheum Dis (2016) 75(1):269&#x2013;77. doi:&#xa0;10.1136/annrheumdis-2014-205958</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-205958</ArticleId><ArticleId IdType="pubmed">25261578</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaz&#x131;l&#x131;ta&#x15f; F, &#xc7;ak&#x131;c&#x131; EK, Kurt &#x15e;&#xfc;k&#xfc;r ED, &#xd6;zdel S, Arda N, G&#xfc;ng&#xf6;r T, et al. . Clinicopathological assessment of kidney biopsies in children with familial mediterranean fever: A single-center experience. Nephron (2020) 144(5):222&#x2013;7. doi:&#xa0;10.1159/000506289</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000506289</ArticleId><ArticleId IdType="pubmed">32172241</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher J, Mohanty T, Karlsson CAQ, Khademi SMH, Malmstrom E, Frigyesi A, et al. . Proteome profiling of recombinant dnase therapy in reducing nets and aiding recovery in covid-19 patients. Mol Cell Proteomics (2021) 20:100113. doi:&#xa0;10.1016/j.mcpro.2021.100113</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcpro.2021.100113</ArticleId><ArticleId IdType="pmc">PMC8205261</ArticleId><ArticleId IdType="pubmed">34139362</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis JC, Manzi S, Yarboro C, Rairie J, McInnes I, Averthelyi D, et al. . Recombinant human Dnase I (Rhdnase) in patients with lupus nephritis. Lupus (1999) 8(1):68&#x2013;76. doi:&#xa0;10.1191/096120399678847380</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120399678847380</ArticleId><ArticleId IdType="pubmed">10025601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad A, Mandwie M, O&#x2019;Sullivan KM, Smyth C, York J, Doyle H, et al. . Conversion of the liver into a biofactory for dnasei using adeno-associated virus vector gene transfer reduces neutrophil extracellular traps in a model of systemic lupus erythematosus. Hum Gene Ther (2022) 33(9-10):560&#x2013;71. doi:&#xa0;10.1089/hum.2021.264</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2021.264</ArticleId><ArticleId IdType="pubmed">35293226</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Zhang Q, Wang F, Guo X, Liu T, Zhao Y, et al. . Hydroxychloroquine inhibiting neutrophil extracellular trap formation alleviates hepatic ischemia/reperfusion injury by blocking tlr9 in mice. Clin Immunol (2020) 216:108461. doi:&#xa0;10.1016/j.clim.2020.108461</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108461</ArticleId><ArticleId IdType="pubmed">32437924</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandler LC, Yusuf IH, McClements ME, Barnard AR, MacLaren RE, Xue K. Immunomodulatory effects of hydroxychloroquine and chloroquine in viral infections and their potential application in retinal gene therapy. Int J Mol Sci (2020) 21(14):4972. doi: 10.3390/ijms21144972</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21144972</ArticleId><ArticleId IdType="pmc">PMC7404262</ArticleId><ArticleId IdType="pubmed">32674481</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamardani TM, Amiritavassoli S. Inhibition of netosis for treatment purposes: friend or foe? Mol Cell Biochem (2022) 477(3):673&#x2013;88. doi:&#xa0;10.1007/s11010-021-04315-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-021-04315-x</ArticleId><ArticleId IdType="pmc">PMC8736330</ArticleId><ArticleId IdType="pubmed">34993747</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Estel GJ, Alarc&#xf3;n GS, McGwin J, Danila MI, Zhang J, Bastian HM, et al. . Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: lxv, data from a multiethnic us cohort. Arthritis Care Res (2009) 61(6):830&#x2013;9. doi:&#xa0;10.1002/art.24538</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24538</ArticleId><ArticleId IdType="pmc">PMC2898742</ArticleId><ArticleId IdType="pubmed">19479701</ArticleId></ArticleIdList></Reference><Reference><Citation>Sis&#xf3; A, Ramos-Casals M, Bov&#xe9; A, Brito-Zer&#xf3;n P, Soria N, Mu&#xf1;oz S, et al. . Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus (2008) 17(4):281&#x2013;8. doi:&#xa0;10.1177/0961203307086503</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203307086503</ArticleId><ArticleId IdType="pubmed">18413408</ArticleId></ArticleIdList></Reference><Reference><Citation>Torigoe M, Obata Y, Inoue H, Torigoe K, Kinoshita A, Koji T, et al. . Hydroxychloroquine suppresses anti-Gbm nephritis via inhibition of Jnk/P38 Mapk signaling. Clin Exp Nephrol (2023) 27(2):110&#x2013;21. doi: 10.1007/s10157-022-02285-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10157-022-02285-y</ArticleId><ArticleId IdType="pubmed">36264415</ArticleId></ArticleIdList></Reference><Reference><Citation>Port A, Shaw JV, Klopp-Schulze L, Bytyqi A, Vetter C, Hussey E, et al. . Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8. Pharmacol Res Perspect (2021) 9(5):e00842. doi:&#xa0;10.1002/prp2.842</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.842</ArticleId><ArticleId IdType="pmc">PMC8377444</ArticleId><ArticleId IdType="pubmed">34414672</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha JJ, Hyun YY, Lee MH, Kim JE, Nam DH, Song HK, et al. . Renal protective effects of toll-like receptor 4 signaling blockade in type 2 diabetic mice. Endocrinology (2013) 154(6):2144&#x2013;55. doi:&#xa0;10.1210/en.2012-2080</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2012-2080</ArticleId><ArticleId IdType="pubmed">23568555</ArticleId></ArticleIdList></Reference><Reference><Citation>Farooq M, Batool M, Kim MS, Choi S. Toll-like receptors as a therapeutic target in the era of immunotherapies. Front Cell Dev Biol (2021) 9:756315. doi:&#xa0;10.3389/fcell.2021.756315</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.756315</ArticleId><ArticleId IdType="pmc">PMC8522911</ArticleId><ArticleId IdType="pubmed">34671606</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Chen Z, Hou S, Liu Z, Lv Q. Tak-242 attenuates crush injury induced acute kidney injury through inhibiting Tlr4/Nf-&#x3ba;b signaling pathways in rats. Prehosp Disaster Med (2020) 35(6):619&#x2013;28. doi:&#xa0;10.1017/s1049023x20001132</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/s1049023x20001132</ArticleId><ArticleId IdType="pubmed">32967743</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan X, Zheng X, Huang Z, Lin J, Xie C, Lin Y. Involvement of S100a8/A9-Tlr4-Nlrp3 inflammasome pathway in contrast-induced acute kidney injury. Cell Physiol Biochem (2017) 43(1):209&#x2013;22. doi:&#xa0;10.1159/000480340</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000480340</ArticleId><ArticleId IdType="pubmed">28854431</ArticleId></ArticleIdList></Reference><Reference><Citation>Salama M, Elgamal M, Abdelaziz A, Ellithy M, Magdy D, Ali L, et al. . Toll-like receptor 4 blocker as potential therapy for acetaminophen-induced organ failure in mice. Exp Ther Med (2015) 10(1):241&#x2013;6. doi:&#xa0;10.3892/etm.2015.2442</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2015.2442</ArticleId><ArticleId IdType="pmc">PMC4487059</ArticleId><ArticleId IdType="pubmed">26170942</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Y, Wu S, Yang Y, Li GQ, Meng L, Zheng QY, et al. . Light aggravates sepsis-associated acute kidney injury via Tlr4-Myd88-Nf-&#x3ba;b pathway. J Cell Mol Med (2020) 24(20):11936&#x2013;48. doi:&#xa0;10.1111/jcmm.15815</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.15815</ArticleId><ArticleId IdType="pmc">PMC7579683</ArticleId><ArticleId IdType="pubmed">32881263</ArticleId></ArticleIdList></Reference><Reference><Citation>Monnet E, Choy EH, McInnes I, Kobakhidze T, Graaf KD, Jacqmin P, et al. . Efficacy and safety of ni-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: A phase Ii study. Ann Rheumatic Dis (2020) 79(3):316&#x2013;23. doi:&#xa0;10.1136/annrheumdis-2019-216487</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-216487</ArticleId><ArticleId IdType="pubmed">31892533</ArticleId></ArticleIdList></Reference><Reference><Citation>Opal SM, Laterre P-F, Francois B, LaRosa SP, Angus DC, Mira J-P, et al. . Effect of eritoran, an antagonist of Md2-Tlr4, on mortality in patients with severe sepsis: the access randomized trial. JAMA (2013) 309(11):1154&#x2013;62. doi:&#xa0;10.1001/jama.2013.2194</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.2194</ArticleId><ArticleId IdType="pubmed">23512062</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta AK, Giaglis S, Hasler P, Hahn S. Efficient neutrophil extracellular trap induction requires mobilization of both intracellular and extracellular calcium pools and is modulated by cyclosporine A. PloS One (2014) 9(5):e97088. doi:&#xa0;10.1371/journal.pone.0097088</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0097088</ArticleId><ArticleId IdType="pmc">PMC4018253</ArticleId><ArticleId IdType="pubmed">24819773</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafael-Vidal C, Altab&#xe1;s I, P&#xe9;rez N, Mourino Rodr&#xed;guez C, Pego-Reigosa JM, Garcia S. Calcineurin and systemic lupus erythematosus: the rationale for using calcineurin inhibitors in the treatment of lupus nephritis. Int J Mol Sci (2021) 22(3):1263. doi: 10.3390/ijms22031263</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22031263</ArticleId><ArticleId IdType="pmc">PMC7865978</ArticleId><ArticleId IdType="pubmed">33514066</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. . 2019 Update of the joint european league against rheumatism and european renal association-European dialysis and transplant association (Eular/Era-Edta) recommendations for the management of lupus nephritis. Ann Rheum Dis (2020) 79(6):713&#x2013;23. doi:&#xa0;10.1136/annrheumdis-2020-216924</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-216924</ArticleId><ArticleId IdType="pubmed">32220834</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Wang H, Liu Y, Yang W, Liu J, Han Y, et al. . Tacrolimus ameliorates tubulointerstitial inflammation in diabetic nephropathy via inhibiting the Nfatc1/Trpc6 pathway. J Cell Mol Med (2020) 24(17):9810&#x2013;24. doi:&#xa0;10.1111/jcmm.15562</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.15562</ArticleId><ArticleId IdType="pmc">PMC7520323</ArticleId><ArticleId IdType="pubmed">32779844</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng T, Chang X, Wang J, Zhen J, Yang X, Hu Z. Protective effects of tacrolimus on podocytes in early diabetic nephropathy in rats. Mol Med Rep (2017) 15(5):3172&#x2013;8. doi:&#xa0;10.3892/mmr.2017.6354</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2017.6354</ArticleId><ArticleId IdType="pubmed">28339051</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung YY, Yao Hui LL, Kraus VB. Colchicine&#x2013;update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum (2015) 45(3):341&#x2013;50. doi:&#xa0;10.1016/j.semarthrit.2015.06.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2015.06.013</ArticleId><ArticleId IdType="pmc">PMC4656054</ArticleId><ArticleId IdType="pubmed">26228647</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettiol A, Becatti M, Silvestri E, Argento FR, Fini E, Mannucci A, et al. . Neutrophil-mediated mechanisms of damage and in-vitro protective effect of colchicine in non-vascular Behcet&#x2019;s syndrome. Clin Exp Immunol (2021) 206(3):410&#x2013;21. doi:&#xa0;10.1111/cei.13664</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13664</ArticleId><ArticleId IdType="pmc">PMC8561698</ArticleId><ArticleId IdType="pubmed">34562315</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis J, Sirois MG, Rh&#xe9;aume E, Nguyen QT, Clavet-Lanthier M, Brand G, et al. . Colchicine reduces lung injury in experimental acute respiratory distress syndrome. PloS One (2020) 15(12):e0242318. doi:&#xa0;10.1371/journal.pone.0242318</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0242318</ArticleId><ArticleId IdType="pmc">PMC7710059</ArticleId><ArticleId IdType="pubmed">33264297</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaidya K, Tucker B, Kurup R, Khandkar C, Pandzic E, Barraclough J, et al. . Colchicine inhibits neutrophil extracellular trap formation in patients with acute coronary syndrome after percutaneous coronary intervention. J Am Heart Assoc (2021) 10(1):e018993. doi:&#xa0;10.1161/JAHA.120.018993</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.120.018993</ArticleId><ArticleId IdType="pmc">PMC7955504</ArticleId><ArticleId IdType="pubmed">33346683</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Peng X, Hu J, Luo T, Wang Z, Cheng Q, et al. . Low-dose colchicine in type 2 diabetes with Microalbuminuria: A double-blind randomized clinical trial. J Diabetes (2021) 13(10):827&#x2013;36. doi:&#xa0;10.1111/1753-0407.13174</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1753-0407.13174</ArticleId><ArticleId IdType="pubmed">33660924</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight JS, Luo W, O&#x2019;Dell AA, Yalavarthi S, Zhao W, Subramanian V, et al. . Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. Circ Res (2014) 114(6):947&#x2013;56. doi:&#xa0;10.1161/CIRCRESAHA.114.303312</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.114.303312</ArticleId><ArticleId IdType="pmc">PMC4185401</ArticleId><ArticleId IdType="pubmed">24425713</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis HD, Liddle J, Coote JE, Atkinson SJ, Barker MD, Bax BD, et al. . Inhibition of Pad4 activity is sufficient to disrupt mouse and human net formation. Nat Chem Biol (2015) 11(3):189&#x2013;91. doi:&#xa0;10.1038/nchembio.1735</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1735</ArticleId><ArticleId IdType="pmc">PMC4397581</ArticleId><ArticleId IdType="pubmed">25622091</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight JS, Zhao W, Luo W, Subramanian V, O&#x2019;Dell AA, Yalavarthi S, et al. . Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J Clin Invest (2013) 123(7):2981&#x2013;93. doi:&#xa0;10.1172/JCI67390</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI67390</ArticleId><ArticleId IdType="pmc">PMC3696545</ArticleId><ArticleId IdType="pubmed">23722903</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight JS, Subramanian V, O&#x2019;Dell AA, Yalavarthi S, Zhao W, Smith CK, et al. . Peptidylarginine deiminase inhibition disrupts net formation and protects against kidney, skin and vascular disease in lupus-prone Mrl/Lpr mice. Ann Rheum Dis (2015) 74(12):2199&#x2013;206. doi:&#xa0;10.1136/annrheumdis-2014-205365</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-205365</ArticleId><ArticleId IdType="pmc">PMC4320672</ArticleId><ArticleId IdType="pubmed">25104775</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon RA, Herter JM, Rosetti F, Campbell AM, Nishi H, Kashgarian M, et al. . Lupus and proliferative nephritis are Pad4 independent in murine models. JCI Insight (2017) 2(10):e92926. doi:&#xa0;10.1172/jci.insight.92926</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.92926</ArticleId><ArticleId IdType="pmc">PMC5436537</ArticleId><ArticleId IdType="pubmed">28515361</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqui AZ, Bhatti UF, Deng Q, Biesterveld BE, Tian Y, Wu Z, et al. . Cl-amidine improves survival and attenuates kidney injury in a rabbit model of endotoxic shock. Surg Infect (2020) 22(4):421&#x2013;6. doi:&#xa0;10.1089/sur.2020.189</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/sur.2020.189</ArticleId><ArticleId IdType="pubmed">32833601</ArticleId></ArticleIdList></Reference><Reference><Citation>Du M, Yang L, Gu J, Wu J, Ma Y, Wang T. Inhibition of peptidyl arginine deiminase-4 prevents renal ischemia-reperfusion-induced remote lung injury. Mediators Inflamm (2020) 2020:1724206. doi:&#xa0;10.1155/2020/1724206</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/1724206</ArticleId><ArticleId IdType="pmc">PMC7787741</ArticleId><ArticleId IdType="pubmed">33456369</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichaiyo S, Svasti S, Supharattanasitthi W, Morales NP. Dasatinib induces loss of vascular integrity and promotes cutaneous wound repair in mice. J Thromb Haemost (2021) 19(12):3154&#x2013;67. doi:&#xa0;10.1111/jth.15499</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15499</ArticleId><ArticleId IdType="pubmed">34402195</ArticleId></ArticleIdList></Reference><Reference><Citation>Telerman A, Granot G, Leibovitch C, Yarchovsky-Dolberg O, Shacham-Abulafia A, Partouche S, et al. . Neutrophil extracellular traps are increased in chronic myeloid leukemia and are differentially affected by tyrosine kinase inhibitors. Cancers (Basel) (2021) 14(1):119. doi:&#xa0;10.3390/cancers14010119</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14010119</ArticleId><ArticleId IdType="pmc">PMC8750902</ArticleId><ArticleId IdType="pubmed">35008283</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller H, Stadtmann A, Van Aken H, Hirsch E, Wang D, Ley K, et al. . Tyrosine kinase Btk regulates E-selectin-mediated integrin activation and neutrophil recruitment by controlling Phospholipase C (Plc) Gamma2 and Pi3kgamma pathways. Blood (2010) 115(15):3118&#x2013;27. doi:&#xa0;10.1182/blood-2009-11-254185</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-11-254185</ArticleId><ArticleId IdType="pmc">PMC2858472</ArticleId><ArticleId IdType="pubmed">20167705</ArticleId></ArticleIdList></Reference><Reference><Citation>Volmering S, Block H, Boras M, Lowell CA, Zarbock A. The neutrophil Btk signalosome regulates integrin activation during sterile inflammation. Immunity (2016) 44(1):73&#x2013;87. doi:&#xa0;10.1016/j.immuni.2015.11.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2015.11.011</ArticleId><ArticleId IdType="pmc">PMC5030078</ArticleId><ArticleId IdType="pubmed">26777396</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangla A, Khare A, Vineeth V, Panday NN, Mukhopadhyay A, Ravindran B, et al. . Pleiotropic consequences of bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses. Blood (2004) 104(4):1191&#x2013;7. doi:&#xa0;10.1182/blood-2004-01-0207</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2004-01-0207</ArticleId><ArticleId IdType="pubmed">15117762</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalmers SA, Glynn E, Garcia SJ, Panzenbeck M, Pelletier J, Dimock J, et al. . Btk inhibition ameliorates kidney disease in spontaneous lupus nephritis. Clin Immunol (2018) 197:205&#x2013;18. doi:&#xa0;10.1016/j.clim.2018.10.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2018.10.008</ArticleId><ArticleId IdType="pmc">PMC6384222</ArticleId><ArticleId IdType="pubmed">30339790</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo-Vizcaya A, Fasano S, Isenberg DA. Bruton&#x2019;s tyrosine kinase inhibitors: A new therapeutic target for the treatment of Sle? Immunotargets Ther (2020) 9:105&#x2013;10. doi:&#xa0;10.2147/ITT.S240874</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/ITT.S240874</ArticleId><ArticleId IdType="pmc">PMC7276208</ArticleId><ArticleId IdType="pubmed">32582577</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutcheson J, Vanarsa K, Bashmakov A, Grewal S, Sajitharan D, Chang BY, et al. . Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus. Arthritis Res Ther (2012) 14(6):R243. doi:&#xa0;10.1186/ar4086</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar4086</ArticleId><ArticleId IdType="pmc">PMC3674619</ArticleId><ArticleId IdType="pubmed">23136880</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, Lei L, Ding H, Chen Y, Pathak S, Hicks J, et al. . Targeting multiple end organs in lupus and other systemic rheumatic diseases by inhibiting Bruton&#x2019;s tyrosine kinase. Front Immunol (2022) 13:893899. doi:&#xa0;10.3389/fimmu.2022.893899</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.893899</ArticleId><ArticleId IdType="pmc">PMC9304663</ArticleId><ArticleId IdType="pubmed">35874767</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Dorner T, Pisetsky DS, Sanchez-Guerrero J, Patel AC, Parsons-Rich D, et al. . Efficacy and safety of the Bruton&#x2019;s tyrosine kinase inhibitor evobrutinib in systemic lupus erythematosus: results of a phase Ii, randomized, double-blind, placebo-controlled dose-ranging trial. ACR Open Rheumatol (2023) 5(1):38&#x2013;48. doi:&#xa0;10.1002/acr2.11511</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11511</ArticleId><ArticleId IdType="pmc">PMC9837396</ArticleId><ArticleId IdType="pubmed">36530019</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg D, Furie R, Jones NS, Guibord P, Galanter J, Lee C, et al. . Efficacy, safety, and pharmacodynamic effects of the Bruton&#x2019;s tyrosine kinase inhibitor Fenebrutinib (Gdc-0853) in systemic lupus erythematosus: results of a phase Ii, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol (2021) 73(10):1835&#x2013;46. doi:&#xa0;10.1002/art.41811</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41811</ArticleId><ArticleId IdType="pubmed">34042314</ArticleId></ArticleIdList></Reference><Reference><Citation>Aksentijevich I. The sickening consequences of too much Syk signaling. Nat Genet (2021) 53(4):432&#x2013;4. doi:&#xa0;10.1038/s41588-021-00837-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00837-8</ArticleId><ArticleId IdType="pubmed">33782606</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewins P, Williams JM, Wakelam MJO, Savage COS. Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fc&#x3b3; Receptors and Cd18. J Am Soc Nephrol (2004) 15(3):796&#x2013;808. doi: 10.1097/01.ASN.0000113241.98702.77</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ASN.0000113241.98702.77</ArticleId><ArticleId IdType="pubmed">14978183</ArticleId></ArticleIdList></Reference><Reference><Citation>McAdoo SP, Prendecki M, Tanna A, Bhatt T, Bhangal G, McDaid J, et al. . Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical model. Kidney Int (2020) 97(6):1196&#x2013;207. doi:&#xa0;10.1016/j.kint.2019.12.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2019.12.014</ArticleId><ArticleId IdType="pmc">PMC7242903</ArticleId><ArticleId IdType="pubmed">32305129</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, et al. . An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheumatism (2008) 58(5):1433&#x2013;44. doi:&#xa0;10.1002/art.23428</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23428</ArticleId><ArticleId IdType="pubmed">18438845</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng GM, Liu L, Bahjat FR, Pine PR, Tsokos GC. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum (2010) 62(7):2086&#x2013;92. doi:&#xa0;10.1002/art.27452</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27452</ArticleId><ArticleId IdType="pmc">PMC2902591</ArticleId><ArticleId IdType="pubmed">20222110</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y, Ma FY, Di Paolo J, Nikolic-Paterson DJ. An inhibitor of spleen tyrosine kinase suppresses experimental crescentic glomerulonephritis. Int J Immunopathol Pharmacol (2018) 32:2058738418783404. doi:&#xa0;10.1177/2058738418783404</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2058738418783404</ArticleId><ArticleId IdType="pmc">PMC6024518</ArticleId><ArticleId IdType="pubmed">29923438</ArticleId></ArticleIdList></Reference><Reference><Citation>Furumoto Y, Smith CK, Blanco L, Zhao W, Brooks SR, Thacker SG, et al. . Tofacitinib ameliorates murine lupus and its associated vascular dysfunction. Arthritis Rheumatol (2017) 69(1):148&#x2013;60. doi:&#xa0;10.1002/art.39818</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39818</ArticleId><ArticleId IdType="pmc">PMC5195893</ArticleId><ArticleId IdType="pubmed">27429362</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Q, Chen W, Song H, Long X, Zhang Z, Tang X, et al. . Tofacitinib ameliorates lupus through suppression of T cell activation mediated by Tgf-beta type I receptor. Front Immunol (2021) 12:675542. doi:&#xa0;10.3389/fimmu.2021.675542</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.675542</ArticleId><ArticleId IdType="pmc">PMC8358742</ArticleId><ArticleId IdType="pubmed">34394075</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, Luo Y, O&#x2019;Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach. Nat Rev Rheumatol (2022) 18(3):133&#x2013;45. doi:&#xa0;10.1038/s41584-021-00726-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-021-00726-8</ArticleId><ArticleId IdType="pmc">PMC8730299</ArticleId><ArticleId IdType="pubmed">34987201</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Bruce IN, Dorner T, Tanaka Y, Morand EF, Kalunian KC, et al. . Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 3 trial (Sle-Brave-Ii). Lancet (2023) 401(10381):1011&#x2013;9. doi:&#xa0;10.1016/S0140-6736(22)02546-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02546-6</ArticleId><ArticleId IdType="pubmed">36848919</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuttle KR, Brosius FC III, Adler SG, Kretzler M, Mehta RL, Tumlin JA, et al. . Jak1/Jak2 inhibition by baricitinib in diabetic kidney disease: results from a phase 2 randomized controlled clinical trial. Nephrol Dialysis Transplant (2018) 33(11):1950&#x2013;9. doi:&#xa0;10.1093/ndt/gfx377</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfx377</ArticleId><ArticleId IdType="pmc">PMC6212720</ArticleId><ArticleId IdType="pubmed">29481660</ArticleId></ArticleIdList></Reference><Reference><Citation>Menne J, Eulberg D, Beyer D, Baumann M, Saudek F, Valkusz Z, et al. . C-C motif-ligand 2 inhibition with emapticap pegol (Nox-E36) in type 2 diabetic patients with Albuminuria. Nephrol Dialysis Transplant (2017) 32(2):307&#x2013;15. doi:&#xa0;10.1093/ndt/gfv459</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfv459</ArticleId><ArticleId IdType="pmc">PMC5410979</ArticleId><ArticleId IdType="pubmed">28186566</ArticleId></ArticleIdList></Reference><Reference><Citation>de Zeeuw D, Bekker P, Henkel E, Hasslacher C, Gouni-Berthold I, Mehling H, et al. . The effect of ccr2 inhibitor ccx140-B on residual Albuminuria in patients with type 2 diabetes and nephropathy: A randomised trial. Lancet Diabetes Endocrinol (2015) 3(9):687&#x2013;96. doi:&#xa0;10.1016/s2213-8587(15)00261-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-8587(15)00261-2</ArticleId><ArticleId IdType="pubmed">26268910</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D, Liu Y, Chen J, Lin H, Guo H, Wu Y, et al. . Jak/Stat pathway promotes the progression of diabetic kidney disease via autophagy in podocytes. Eur J Pharmacol (2021) 902:174121. doi:&#xa0;10.1016/j.ejphar.2021.174121</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2021.174121</ArticleId><ArticleId IdType="pubmed">33901462</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Kady MM, Naggar RA, Guimei M, Talaat IM, Shaker OG, Saber-Ayad M. Early renoprotective effect of Ruxolitinib in a rat model of diabetic nephropathy. Pharm (Basel) (2021) 14(7):608. doi:&#xa0;10.3390/ph14070608</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14070608</ArticleId><ArticleId IdType="pmc">PMC8308627</ArticleId><ArticleId IdType="pubmed">34202668</ArticleId></ArticleIdList></Reference><Reference><Citation>Markovi&#x107; DC, Maslovari&#x107; IS, Kova&#x10d;i&#x107; M, Vignjevi&#x107; Petrinovi&#x107; S, Ili&#x107; VL. Putative role of neutrophil extracellular trap formation in chronic myeloproliferative neoplasms. Int J Mol Sci (2023) 24(5):4497. doi: 10.3390/ijms24054497</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24054497</ArticleId><ArticleId IdType="pmc">PMC10003516</ArticleId><ArticleId IdType="pubmed">36901933</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolach O, Sellar RS, Martinod K, Cherpokova D, McConkey M, Chappell RJ, et al. . Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med (2018) 10(436):eaan8292. doi:&#xa0;10.1126/scitranslmed.aan8292</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aan8292</ArticleId><ArticleId IdType="pmc">PMC6442466</ArticleId><ArticleId IdType="pubmed">29643232</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun Y, Chen J, Wang X, Li Y, Hu Z, Yang P, et al. . Tofacitinib ameliorates lipopolysaccharide-induced acute kidney injury by blocking the Jak-Stat1/Stat3 signaling pathway. BioMed Res Int (2021) 2021:8877056. doi:&#xa0;10.1155/2021/8877056</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/8877056</ArticleId><ArticleId IdType="pmc">PMC7822662</ArticleId><ArticleId IdType="pubmed">33511217</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Xu W, Zhu H. Cxcl8((3-72)) K11r/G31p protects against sepsis-induced acute kidney injury via Nf-&#x3ba;b and Jak2/Stat3 pathway. Biol Res (2019) 52(1):29. doi:&#xa0;10.1186/s40659-019-0236-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40659-019-0236-5</ArticleId><ArticleId IdType="pmc">PMC6513525</ArticleId><ArticleId IdType="pubmed">31084615</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne DRW, Merkel PA, Schall TJ, Bekker P. Avacopan for the treatment of anca-associated vasculitis. New Engl J Med (2021) 384(7):599&#x2013;609. doi:&#xa0;10.1056/NEJMoa2023386</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023386</ArticleId><ArticleId IdType="pubmed">33596356</ArticleId></ArticleIdList></Reference><Reference><Citation>Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. . Terminal complement inhibitor Eculizumab in atypical hemolytic&#x2013;uremic syndrome. New Engl J Med (2013) 368(23):2169&#x2013;81. doi:&#xa0;10.1056/NEJMoa1208981</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1208981</ArticleId><ArticleId IdType="pubmed">23738544</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright RD, Bannerman F, Beresford MW, Oni L. A systematic review of the role of Eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy. BMC Nephrol (2020) 21(1):245. doi:&#xa0;10.1186/s12882-020-01888-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-020-01888-5</ArticleId><ArticleId IdType="pmc">PMC7329551</ArticleId><ArticleId IdType="pubmed">32605540</ArticleId></ArticleIdList></Reference><Reference><Citation>Nithagon P, Cortazar F, Shah SI, Weins A, Laliberte K, Jeyabalan A, et al. . Eculizumab and complement activation in anti-glomerular basement membrane disease. Kidney Int Rep (2021) 6(10):2713&#x2013;7. doi:&#xa0;10.1016/j.ekir.2021.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2021.07.001</ArticleId><ArticleId IdType="pmc">PMC8484114</ArticleId><ArticleId IdType="pubmed">34622110</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalunian KC, Merrill JT, Maciuca R, McBride JM, Townsend MJ, Wei X, et al. . A phase ii study of the efficacy and safety of Rontalizumab (Rhumab Interferon-&#x3b1;) in patients with systemic lupus erythematosus (Rose). Ann Rheum Dis (2016) 75(1):196&#x2013;202. doi:&#xa0;10.1136/annrheumdis-2014-206090</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-206090</ArticleId><ArticleId IdType="pubmed">26038091</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi T, Tanaka Y, Matsumura R, Saito K, Yoshimura M, Amano K, et al. . Safety and tolerability of sifalimumab, an anti-interferon-&#x3b1; Monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study. Modern Rheumatol (2020) 30(1):93&#x2013;100. doi:&#xa0;10.1080/14397595.2019.1583832</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14397595.2019.1583832</ArticleId><ArticleId IdType="pubmed">30791804</ArticleId></ArticleIdList></Reference><Reference><Citation>Casey KA, Guo X, Smith MA, Wang S, Sinibaldi D, Sanjuan MA, et al. . Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of sle. Lupus Sci Med (2018) 5(1):e000286. doi:&#xa0;10.1136/lupus-2018-000286</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000286</ArticleId><ArticleId IdType="pmc">PMC6257383</ArticleId><ArticleId IdType="pubmed">30538817</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. . Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med (2019) 382(3):211&#x2013;21. doi:&#xa0;10.1056/NEJMoa1912196</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne D, Rovin B, Mysler EF, Furie RA, Houssiau FA, Trasieva T, et al. . Phase ii randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheumatic Dis (2022) 81(4):496&#x2013;506. doi:&#xa0;10.1136/annrheumdis-2021-221478</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221478</ArticleId><ArticleId IdType="pmc">PMC8921596</ArticleId><ArticleId IdType="pubmed">35144924</ArticleId></ArticleIdList></Reference><Reference><Citation>Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, et al. . Belimumab reduces autoantibodies, norMalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum (2012) 64(7):2328&#x2013;37. doi:&#xa0;10.1002/art.34400</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34400</ArticleId><ArticleId IdType="pmc">PMC3350827</ArticleId><ArticleId IdType="pubmed">22275291</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman CL, Sehn LH. A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol (2018) 182(1):29&#x2013;45. doi:&#xa0;10.1111/bjh.15232</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.15232</ArticleId><ArticleId IdType="pubmed">29741753</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. . Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum (2012) 64(4):1215&#x2013;26. doi:&#xa0;10.1002/art.34359</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34359</ArticleId><ArticleId IdType="pubmed">22231479</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. . Kdigo 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int (2021) 100(4):S1&#x2013;S276. doi:&#xa0;10.1016/j.kint.2021.05.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.05.021</ArticleId><ArticleId IdType="pubmed">34556256</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. . Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med (2020) 383(12):1117&#x2013;28. doi:&#xa0;10.1056/NEJMoa2001180</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001180</ArticleId><ArticleId IdType="pubmed">32937045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraaij T, Kamerling SWA, de Rooij ENM, van Daele PLA, Bredewold OW, Bakker JA, et al. . The net-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun (2018) 91:45&#x2013;54. doi:&#xa0;10.1016/j.jaut.2018.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2018.03.003</ArticleId><ArticleId IdType="pubmed">29636274</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann J, Roesner S, Neubauer A. Rituximab induces a flare-up of activated neutrophil extracellular traps under in vitro conditions. Immunopharmacol Immunotoxicol (2022) 44(6):860&#x2013;7. doi:&#xa0;10.1080/08923973.2022.2088386</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08923973.2022.2088386</ArticleId><ArticleId IdType="pubmed">35695816</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al. . B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: A randomised, double-blind, placebo-controlled trial. Ann Rheum Dis (2022) 81(1):100&#x2013;7. doi:&#xa0;10.1136/annrheumdis-2021-220920</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220920</ArticleId><ArticleId IdType="pmc">PMC8762029</ArticleId><ArticleId IdType="pubmed">34615636</ArticleId></ArticleIdList></Reference><Reference><Citation>Unizony S, Villarreal M, Miloslavsky EM, Lu N, Merkel PA, Spiera R, et al. . Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (Anca)-associated vasculitis based on Anca type. Ann Rheumatic Dis (2016) 75(6):1166&#x2013;9. doi:&#xa0;10.1136/annrheumdis-2015-208073</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-208073</ArticleId><ArticleId IdType="pmc">PMC4908815</ArticleId><ArticleId IdType="pubmed">26621483</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RM, Jones RB, Specks U, Bond S, Nodale M, Aljayyousi R, et al. . Rituximab as therapy to induce remission after relapse in anca-associated vasculitis. Ann Rheum Dis (2020) 79(9):1243&#x2013;9. doi:&#xa0;10.1136/annrheumdis-2019-216863</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-216863</ArticleId><ArticleId IdType="pmc">PMC7456549</ArticleId><ArticleId IdType="pubmed">32581088</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain R, Dgheim H, Bomback AS. Rituximab for anti-glomerular basement membrane disease. Kidney Int Rep (2019) 4(4):614&#x2013;8. doi:&#xa0;10.1016/j.ekir.2018.12.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2018.12.002</ArticleId><ArticleId IdType="pmc">PMC6451084</ArticleId><ArticleId IdType="pubmed">30993238</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Strand V, Merrill JT, Popa S, Spindler AJ, Eimon A, et al. . Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: A phase Ii dose-ranging randomised controlled trial. Ann Rheumatic Dis (2017) 76(3):534&#x2013;42. doi:&#xa0;10.1136/annrheumdis-2016-209668</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-209668</ArticleId><ArticleId IdType="pmc">PMC5446001</ArticleId><ArticleId IdType="pubmed">27672124</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei C-T, Su H, Ye C, Tang H, Gao P, Wan C, et al. . The classic signalling and trans-signalling of interleukin-6 are both injurious in podocyte under high glucose exposure. J Cell Mol Med (2018) 22(1):251&#x2013;60. doi:&#xa0;10.1111/jcmm.13314</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.13314</ArticleId><ArticleId IdType="pmc">PMC5742688</ArticleId><ArticleId IdType="pubmed">28881473</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelrahman AM, Al Suleimani Y, Shalaby A, Ashique M, Manoj P, Ali BH. Effect of tocilizumab, an interleukin-6 inhibitor, on early stage streptozotocin-induced diabetic nephropathy in rats. Naunyn Schmiedebergs Arch Pharmacol (2019) 392(8):1005&#x2013;13. doi:&#xa0;10.1007/s00210-019-01655-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00210-019-01655-w</ArticleId><ArticleId IdType="pubmed">31025143</ArticleId></ArticleIdList></Reference><Reference><Citation>Toriu N, Yamanouchi M, Hiramatsu R, Hayami N, Hoshino J, Sekine A, et al. . Tocilizumab prevents renal function of a patient with diabetic kidney disease: case report. Modern Rheumatol Case Rep (2019) 3(1):53&#x2013;6. doi:&#xa0;10.1080/24725625.2018.1477489</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/24725625.2018.1477489</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadehn H, Raluy LP, Kolman J, Duecker C, Trochimiuk M, Appl B, et al. . Time- and dose-dependent inhibition of neutrophil extracellular trap formation by blocking of the interleukin-1 receptor. Cent Eur J Immunol (2021) 46(4):419&#x2013;26. doi:&#xa0;10.5114/ceji.2021.111493</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/ceji.2021.111493</ArticleId><ArticleId IdType="pmc">PMC8808312</ArticleId><ArticleId IdType="pubmed">35125939</ArticleId></ArticleIdList></Reference><Reference><Citation>Sil P, Wicklum H, Surell C, Rada B. Macrophage-derived il-1&#x3b2; Enhances monosodium urate crystal-triggered net formation. Inflamm Res (2017) 66(3):227&#x2013;37. doi:&#xa0;10.1007/s00011-016-1008-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-016-1008-0</ArticleId><ArticleId IdType="pmc">PMC5296223</ArticleId><ArticleId IdType="pubmed">27853847</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein AL, Imazio M, Cremer P, Brucato A, Abbate A, Fang F, et al. . Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis. N Engl J Med (2021) 384(1):31&#x2013;41. doi:&#xa0;10.1056/NEJMoa2027892</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2027892</ArticleId><ArticleId IdType="pubmed">33200890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wlodek E, Kirkpatrick RB, Andrews S, Noble R, Schroyer R, Scott J, et al. . A pilot study evaluating gsk1070806 inhibition of interleukin-18 in renal transplant delayed graft function. PloS One (2021) 16(3):e0247972. doi:&#xa0;10.1371/journal.pone.0247972</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0247972</ArticleId><ArticleId IdType="pmc">PMC7939287</ArticleId><ArticleId IdType="pubmed">33684160</ArticleId></ArticleIdList></Reference><Reference><Citation>McKie EA, Reid JL, Mistry PC, DeWall SL, Abberley L, Ambery PD, et al. . A study to investigate the efficacy and safety of an anti-interleukin-18 monoclonal antibody in the treatment of type 2 diabetes mellitus. PloS One (2016) 11(3):e0150018. doi:&#xa0;10.1371/journal.pone.0150018</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0150018</ArticleId><ArticleId IdType="pmc">PMC4773233</ArticleId><ArticleId IdType="pubmed">26930607</ArticleId></ArticleIdList></Reference><Reference><Citation>Vecchie A, Bonaventura A, Toldo S, Dagna L, Dinarello CA, Abbate A. Il-18 and infections: is there a role for targeted therapies? J Cell Physiol (2021) 236(3):1638&#x2013;57. doi:&#xa0;10.1002/jcp.30008</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.30008</ArticleId><ArticleId IdType="pubmed">32794180</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu HC, Zhang W, Xiong PY, Song L, Jia B, Liu XL. Anti-inflammatory and antioxidant activity of astragalus polysaccharide in ulcerative colitis: A systematic review and meta-analysis of animal studies. Front Pharmacol (2022) 13:1043236. doi:&#xa0;10.3389/fphar.2022.1043236</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.1043236</ArticleId><ArticleId IdType="pmc">PMC9755193</ArticleId><ArticleId IdType="pubmed">36532736</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapponi MJ, Carestia A, Landoni VI, Rivadeneyra L, Etulain J, Negrotto S, et al. . Regulation of neutrophil extracellular trap formation by anti-inflammatory drugs. J Pharmacol Exp Ther (2013) 345(3):430&#x2013;7. doi:&#xa0;10.1124/jpet.112.202879</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.112.202879</ArticleId><ArticleId IdType="pubmed">23536315</ArticleId></ArticleIdList></Reference><Reference><Citation>Zawrotniak M, Kozik A, Rapala-Kozik M. Selected mucolytic, anti-inflammatory and cardiovascular drugs change the ability of neutrophils to form extracellular traps (Nets). Acta Biochim Pol (2015) 62(3):465&#x2013;73. doi:&#xa0;10.18388/abp.2015_1055</Citation><ArticleIdList><ArticleId IdType="doi">10.18388/abp.2015_1055</ArticleId><ArticleId IdType="pubmed">26291043</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee ES, Kim HM, Kang JS, Lee EY, Yadav D, Kwon M-H, et al. . Oleanolic acid and N-acetylcysteine ameliorate diabetic nephropathy through reduction of oxidative stress and endoplasmic reticulum stress in a type 2 diabetic rat model. Nephrol Dialysis Transplant (2016) 31(3):391&#x2013;400. doi:&#xa0;10.1093/ndt/gfv377</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfv377</ArticleId><ArticleId IdType="pubmed">26567248</ArticleId></ArticleIdList></Reference><Reference><Citation>Nogueira GB, Punaro GR, Oliveira CS, Maciel FR, Fernandes TO, Lima DY, et al. . N-Acetylcysteine Protects against Diabetic Nephropathy through Control of Oxidative and Nitrosative Stress by Recovery of Nitric Oxide in Rats. Nitric Oxide (2018) 78:22&#x2013;31. doi:&#xa0;10.1016/j.niox.2018.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.niox.2018.05.003</ArticleId><ArticleId IdType="pubmed">29778909</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbasifard M, Khorramdelazad H, Rostamian A, Rezaian M, Askari PS, Sharifi GTK, et al. . Effects of N-acetylcysteine on systemic lupus erythematosus disease activity and its associated complications: A randomized double-blind clinical trial study. Trials (2023) 24(1):129. doi:&#xa0;10.1186/s13063-023-07083-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-023-07083-9</ArticleId><ArticleId IdType="pmc">PMC9945717</ArticleId><ArticleId IdType="pubmed">36810107</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu B-G, Lee R-P, Yang F-L, Harn H-J, Chen HI. Post-treatment with N-acetylcysteine ameliorates endotoxin shock-induced organ damage in conscious rats. Life Sci (2006) 79(21):2010&#x2013;6. doi:&#xa0;10.1016/j.lfs.2006.06.040</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2006.06.040</ArticleId><ArticleId IdType="pubmed">16860347</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan H, Le J-w, Zhu J-h. Protective effect of N-acetylcysteine pretreatment on acute kidney injury in septic rats. J Surg Res (2020) 254:125&#x2013;34. doi:&#xa0;10.1016/j.jss.2020.04.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jss.2020.04.017</ArticleId><ArticleId IdType="pubmed">32438104</ArticleId></ArticleIdList></Reference><Reference><Citation>Spapen HD, Diltoer MW, Nguyen DN, Hendrickx I, Huyghens LP. Effects of N-acetylcysteine on microalbuminuria and organ failure in acute severe sepsis: results of a pilot study. Chest (2005) 127(4):1413&#x2013;9. doi:&#xa0;10.1378/chest.127.4.1413</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.127.4.1413</ArticleId><ArticleId IdType="pubmed">15821223</ArticleId></ArticleIdList></Reference><Reference><Citation>Najafi A, Mojtahedzadeh M, Ahmadi KH, Abdollahi M, Mousavi M, Chelkeba L, et al. . The immunological benefit of higher dose N-acetyl cysteine following mechanical ventilation in critically ill patients. Daru (2014) 22(1):57. doi:&#xa0;10.1186/2008-2231-22-57</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2008-2231-22-57</ArticleId><ArticleId IdType="pmc">PMC4223415</ArticleId><ArticleId IdType="pubmed">25027749</ArticleId></ArticleIdList></Reference><Reference><Citation>Peake SL, Moran JL, Leppard PI. N-acetyl-L-cysteine depresses cardiac performance in patients with septic shock. Crit Care Med (1996) 24(8):1302&#x2013;10. doi:&#xa0;10.1097/00003246-199608000-00006</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199608000-00006</ArticleId><ArticleId IdType="pubmed">8706483</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe M, Borges FT, Pessoa EA, Fonseca CD, Fernandes SM, Drew RC, et al. . Renoprotective effect of N-acetylcysteine depends upon the severity of the ischemia reperfusion injury. Braz J Med Biol Res (2021) 54(11):e9941. doi: 10.1590/1414-431x2021e9941</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1414-431x2021e9941</ArticleId><ArticleId IdType="pmc">PMC8427747</ArticleId><ArticleId IdType="pubmed">34495252</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandilands EA, Rees JMB, Raja K, Dhaun N, Morrison EE, Hickson K, et al. . Acetylcysteine has no mechanistic effect in patients at risk of contrast-induced nephropathy: A failure of academic clinical science. Clin Pharmacol Ther (2022) 111(6):1222&#x2013;38. doi:&#xa0;10.1002/cpt.2541</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.2541</ArticleId><ArticleId IdType="pmc">PMC9306485</ArticleId><ArticleId IdType="pubmed">35098531</ArticleId></ArticleIdList></Reference><Reference><Citation>Menegazzo L, Scattolini V, Cappellari R, Bonora BM, Albiero M, Bortolozzi M, et al. . The antidiabetic drug metformin blunts netosis in vitro and reduces circulating netosis biomarkers in vivo. Acta Diabetol (2018) 55(6):593&#x2013;601. doi:&#xa0;10.1007/s00592-018-1129-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00592-018-1129-8</ArticleId><ArticleId IdType="pubmed">29546579</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao-cui C, Dan W, Hong-luan W, Hui-yuan L, Chen Y, Hong-yong S, et al. . Metformin improves renal injury of Mrl/Lpr lupus-prone mice via the Ampk/Stat3 pathway. Lupus Sci Med (2022) 9(1):e000611. doi:&#xa0;10.1136/lupus-2021-000611</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000611</ArticleId><ArticleId IdType="pmc">PMC9006817</ArticleId><ArticleId IdType="pubmed">35414608</ArticleId></ArticleIdList></Reference><Reference><Citation>Fangfang S, Shikai G, Haiting W, Huijing W, Zhe L, Xiaodong W, et al. . Effects of metformin on disease flares in patients with systemic lupus erythematosus: post hoc analyses from two randomised trials. Lupus Sci Med (2020) 7(1):e000429. doi:&#xa0;10.1136/lupus-2020-000429</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000429</ArticleId><ArticleId IdType="pmc">PMC7583791</ArticleId><ArticleId IdType="pubmed">33093216</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Metformin inhibits advanced glycation end products (Ages)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for ages (Rage) expression. Horm Metab Res (2012) 44(12):891&#x2013;5. doi:&#xa0;10.1055/s-0032-1321878</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0032-1321878</ArticleId><ArticleId IdType="pubmed">22864903</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawanami D, Takashi Y, Tanabe M. Significance of metformin use in diabetic kidney disease. Int J Mol Sci (2020) 21(12):4239. doi:&#xa0;10.3390/ijms21124239</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21124239</ArticleId><ArticleId IdType="pmc">PMC7352798</ArticleId><ArticleId IdType="pubmed">32545901</ArticleId></ArticleIdList></Reference><Reference><Citation>Clementi ME, Pizzoferrato M, Bianchetti G, Brancato A, Sampaolese B, Maulucci G, et al. . Cytoprotective effect of idebenone through modulation of the intrinsic mitochondrial pathway of apoptosis in human retinal pigment epithelial cells exposed to oxidative stress induced by hydrogen peroxide. Biomedicines (2022) 10(2):503. doi: 10.3390/biomedicines10020503</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10020503</ArticleId><ArticleId IdType="pmc">PMC8962354</ArticleId><ArticleId IdType="pubmed">35203712</ArticleId></ArticleIdList></Reference><Reference><Citation>Ning X, Wang WM, Jin HZ. Low-density granulocytes in immune-mediated inflammatory diseases. J Immunol Res (2022) 2022:1622160. doi:&#xa0;10.1155/2022/1622160</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/1622160</ArticleId><ArticleId IdType="pmc">PMC8820945</ArticleId><ArticleId IdType="pubmed">35141336</ArticleId></ArticleIdList></Reference><Reference><Citation>Handono K, Sidarta YO, Pradana BA, Nugroho RA, Hartono IA, Kalim H, et al. . Vitamin D prevents endothelial damage induced by increased neutrophil extracellular traps formation in patients with systemic lupus erythematosus. Acta Med Indones (2014) 46(3):189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">25348181</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumethkul K, Boonyaratavej S, Kitumnuaypong T, Angthararuk S, Cheewasat P, Manadee N, et al. . The predictive factors of low serum 25-hydroxyvitamin D and vitamin D deficiency in patients with systemic lupus erythematosus. Rheumatol Int (2013) 33(6):1461&#x2013;7. doi:&#xa0;10.1007/s00296-012-2537-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-012-2537-7</ArticleId><ArticleId IdType="pubmed">23179257</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Bello KJ, Fang H, Magder LS. Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. Arthritis Rheumatism (2013) 65(7):1865&#x2013;71. doi:&#xa0;10.1002/art.37953</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.37953</ArticleId><ArticleId IdType="pmc">PMC3701725</ArticleId><ArticleId IdType="pubmed">23553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon T, Ahn SS, Pyo JY, Song JJ, Park YB, Lee SW. Serum vitamin d level correlates with disease activity and health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis. Z F&#xfc;r Rheumatol (2022) 81(1):77&#x2013;84. doi:&#xa0;10.1007/s00393-020-00949-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00393-020-00949-2</ArticleId><ArticleId IdType="pubmed">33340057</ArticleId></ArticleIdList></Reference><Reference><Citation>Joergensen C, Tarnow L, Goetze JP, Rossing P. Vitamin D analogue therapy, cardiovascular risk and kidney function in people with type 1 diabetes mellitus and diabetic nephropathy: A randomized trial. Diabetic Med (2015) 32(3):374&#x2013;81. doi:&#xa0;10.1111/dme.12606</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dme.12606</ArticleId><ArticleId IdType="pubmed">25307511</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Ju&#xe1;rez G, Lu&#xf1;o J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, et al. . 25 (Oh) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system. Clin J Am Soc Nephrol (2013) 8(11):1870&#x2013;6. doi: 10.2215/CJN.00910113</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.00910113</ArticleId><ArticleId IdType="pmc">PMC3817897</ArticleId><ArticleId IdType="pubmed">24135218</ArticleId></ArticleIdList></Reference><Reference><Citation>Graidis S, Papavramidis TS, Papaioannou M. Vitamin D and acute kidney injury: A two-way causality relation and a predictive, prognostic, and therapeutic role of vitamin D. Front Nutr (2020) 7:630951. doi:&#xa0;10.3389/fnut.2020.630951</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2020.630951</ArticleId><ArticleId IdType="pmc">PMC7969500</ArticleId><ArticleId IdType="pubmed">33748167</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun AB, Litonjua AA, Moromizato T, Gibbons FK, Giovannucci E, Christopher KB. Association of low serum 25-hydroxyvitamin D levels and acute kidney injury in the critically ill. Crit Care Med (2012) 40(12):3170&#x2013;9. doi:&#xa0;10.1097/CCM.0b013e318260c928</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e318260c928</ArticleId><ArticleId IdType="pubmed">22975885</ArticleId></ArticleIdList></Reference><Reference><Citation>Bystrzycka W, Manda-Handzlik A, Sieczkowska S, Moskalik A, Demkow U, Ciepiela O. Azithromycin and chloramphenicol diminish neutrophil extracellular traps (Nets) release. Int J Mol Sci (2017) 18(12):2666. doi: 10.3390/ijms18122666</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18122666</ArticleId><ArticleId IdType="pmc">PMC5751268</ArticleId><ArticleId IdType="pubmed">29292737</ArticleId></ArticleIdList></Reference><Reference><Citation>Manda-Handzlik A, Bystrzycka W, Sieczkowska S, Demkow U, Ciepiela O. Antibiotics modulate the ability of neutrophils to release neutrophil extracellular traps. Adv Exp Med Biol (2016) 944:47&#x2013;52. doi: 10.1007/5584_2016_59</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/5584_2016_59</ArticleId><ArticleId IdType="pubmed">27826884</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu JJ, Liu X, Xia S, Zhang Z, Zhang Y, Zhao J, et al. . Fda-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat Immunol (2020) 21(7):736&#x2013;45. doi:&#xa0;10.1038/s41590-020-0669-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0669-6</ArticleId><ArticleId IdType="pmc">PMC7316630</ArticleId><ArticleId IdType="pubmed">32367036</ArticleId></ArticleIdList></Reference><Reference><Citation>Sollberger G, Choidas A, Burn GL, Habenberger P, Di Lucrezia R, Kordes S, et al. . Gasdermin D plays a vital role in the generation of neutrophil extracellular traps. Sci Immunol (2018) 3(26):eaar6689. doi:&#xa0;10.1126/sciimmunol.aar6689</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.aar6689</ArticleId><ArticleId IdType="pubmed">30143555</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray RD, Lucas CD, MacKellar A, Li F, Hiersemenzel K, Haslett C, et al. . Activation of conventional protein kinase C (Pkc) is critical in the generation of human neutrophil extracellular traps. J Inflamm (2013) 10(1):12. doi:&#xa0;10.1186/1476-9255-10-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1476-9255-10-12</ArticleId><ArticleId IdType="pmc">PMC3643828</ArticleId><ArticleId IdType="pubmed">23514610</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashida T, Schnaper HW. High ambient glucose enhances sensitivity to tgf-beta1 via extracellular signal&#x2013;regulated kinase and protein kinase cdelta activities in human mesangial cells. J Am Soc Nephrol (2004) 15(8):2032&#x2013;41. doi:&#xa0;10.1097/01.ASN.0000133198.74973.60</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ASN.0000133198.74973.60</ArticleId><ArticleId IdType="pubmed">15284289</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar-Gonzalez H, Zepeda-Hernandez A, Melo Z, Saavedra-Mayorga DE, Echavarria R. Neutrophil extracellular traps in the establishment and progression of renal diseases. Med (Kaunas) (2019) 55(8):431. doi:&#xa0;10.3390/medicina55080431</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina55080431</ArticleId><ArticleId IdType="pmc">PMC6722876</ArticleId><ArticleId IdType="pubmed">31382486</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakazawa D, Marschner JA, Platen L, Anders HJ. Extracellular traps in kidney disease. Kidney Int (2018) 94(6):1087&#x2013;98. doi:&#xa0;10.1016/j.kint.2018.08.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2018.08.035</ArticleId><ArticleId IdType="pubmed">30466565</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>